Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC raised its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) by 126.3% in the third quarter, Holdings Channel reports. The fund owned 10,189 shares of the company’s stock after buying an additional 5,687 shares during the period. Tower Research Capital LLC TRC’s holdings in Crinetics Pharmaceuticals were worth $200,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Great West Life Assurance Co. Can acquired a new stake in Crinetics Pharmaceuticals in the 3rd quarter valued at about $29,000. High Net Worth Advisory Group LLC purchased a new stake in shares of Crinetics Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Cubist Systematic Strategies LLC grew its stake in shares of Crinetics Pharmaceuticals by 70.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 8,478 shares of the company’s stock valued at $158,000 after buying an additional 3,503 shares during the period. Group One Trading L.P. grew its stake in shares of Crinetics Pharmaceuticals by 31.6% in the 1st quarter. Group One Trading L.P. now owns 7,318 shares of the company’s stock valued at $161,000 after buying an additional 1,759 shares during the period. Finally, PDT Partners LLC purchased a new stake in shares of Crinetics Pharmaceuticals in the 1st quarter valued at approximately $220,000. Institutional investors and hedge funds own 95.64% of the company’s stock.

Analyst Ratings Changes

CRNX has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Crinetics Pharmaceuticals in a research note on Wednesday, March 1st. JMP Securities dropped their price target on shares of Crinetics Pharmaceuticals from $50.00 to $41.00 and set a “market outperform” rating for the company in a research note on Wednesday, March 1st.

Insider Buying and Selling

In related news, insider Stephen F. Betz sold 3,126 shares of the stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $18.00, for a total transaction of $56,268.00. Following the completion of the transaction, the insider now owns 76,151 shares of the company’s stock, valued at approximately $1,370,718. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Stephen F. Betz sold 3,126 shares of the stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $18.00, for a total transaction of $56,268.00. Following the completion of the transaction, the insider now owns 76,151 shares of the company’s stock, valued at approximately $1,370,718. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stephen F. Betz sold 8,336 shares of the stock in a transaction that occurred on Wednesday, January 25th. The stock was sold at an average price of $21.07, for a total transaction of $175,639.52. Following the sale, the insider now owns 67,815 shares in the company, valued at $1,428,862.05. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,588 shares of company stock valued at $281,924. Company insiders own 5.90% of the company’s stock.

Crinetics Pharmaceuticals Stock Performance

NASDAQ:CRNX opened at $18.87 on Tuesday. The stock has a market capitalization of $1.02 billion, a P/E ratio of -5.97 and a beta of 0.97. The company has a 50 day moving average price of $19.11 and a 200 day moving average price of $18.71. Crinetics Pharmaceuticals, Inc. has a fifty-two week low of $15.37 and a fifty-two week high of $27.86.

Crinetics Pharmaceuticals Profile

(Get Rating)

Crinetics Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly.